ATNM
Price
$1.16
Change
-$0.00 (-0.00%)
Updated
Feb 5, 04:59 PM (EDT)
Capitalization
36.19M
36 days until earnings call
Intraday BUY SELL Signals
OCUL
Price
$9.29
Change
+$0.74 (+8.65%)
Updated
Feb 5, 03:30 PM (EDT)
Capitalization
1.82B
32 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ATNM vs OCUL

Header iconATNM vs OCUL Comparison
Open Charts ATNM vs OCULBanner chart's image
Actinium Pharmaceuticals
Price$1.16
Change-$0.00 (-0.00%)
Volume$1.02K
Capitalization36.19M
Ocular Therapeutix
Price$9.29
Change+$0.74 (+8.65%)
Volume$36.33K
Capitalization1.82B
ATNM vs OCUL Comparison Chart in %
ATNM
Daily Signal:
Gain/Loss:
OCUL
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
ATNM vs. OCUL commentary
Feb 05, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ATNM is a Hold and OCUL is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Feb 05, 2026
Stock price -- (ATNM: $1.16 vs. OCUL: $8.55)
Brand notoriety: ATNM and OCUL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ATNM: 88% vs. OCUL: 150%
Market capitalization -- ATNM: $36.19M vs. OCUL: $1.82B
ATNM [@Biotechnology] is valued at $36.19M. OCUL’s [@Biotechnology] market capitalization is $1.82B. The market cap for tickers in the [@Biotechnology] industry ranges from $119.38B to $0. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ATNM’s FA Score shows that 0 FA rating(s) are green whileOCUL’s FA Score has 0 green FA rating(s).

  • ATNM’s FA Score: 0 green, 5 red.
  • OCUL’s FA Score: 0 green, 5 red.
According to our system of comparison, OCUL is a better buy in the long-term than ATNM.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ATNM’s TA Score shows that 4 TA indicator(s) are bullish while OCUL’s TA Score has 4 bullish TA indicator(s).

  • ATNM’s TA Score: 4 bullish, 6 bearish.
  • OCUL’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, both ATNM and OCUL are a bad buy in the short-term.

Price Growth

ATNM (@Biotechnology) experienced а -4.92% price change this week, while OCUL (@Biotechnology) price change was -16.83% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -5.81%. For the same industry, the average monthly price growth was -1.54%, and the average quarterly price growth was +30.06%.

Reported Earning Dates

ATNM is expected to report earnings on Mar 13, 2026.

OCUL is expected to report earnings on Mar 09, 2026.

Industries' Descriptions

@Biotechnology (-5.81% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
OCUL($1.82B) has a higher market cap than ATNM($36.2M). ATNM YTD gains are higher at: -14.706 vs. OCUL (-29.572). ATNM has higher annual earnings (EBITDA): -36.52M vs. OCUL (-233.54M). OCUL has more cash in the bank: 345M vs. ATNM (53.4M). ATNM has less debt than OCUL: ATNM (1.14M) vs OCUL (77M). OCUL has higher revenues than ATNM: OCUL (55.8M) vs ATNM (90K).
ATNMOCULATNM / OCUL
Capitalization36.2M1.82B2%
EBITDA-36.52M-233.54M16%
Gain YTD-14.706-29.57250%
P/E RatioN/AN/A-
Revenue90K55.8M0%
Total Cash53.4M345M15%
Total Debt1.14M77M1%
FUNDAMENTALS RATINGS
ATNM vs OCUL: Fundamental Ratings
ATNM
OCUL
OUTLOOK RATING
1..100
5465
VALUATION
overvalued / fair valued / undervalued
1..100
60
Fair valued
45
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9998
PRICE GROWTH RATING
1..100
6465
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

OCUL's Valuation (45) in the Pharmaceuticals Other industry is in the same range as ATNM (60) in the Biotechnology industry. This means that OCUL’s stock grew similarly to ATNM’s over the last 12 months.

OCUL's Profit vs Risk Rating (100) in the Pharmaceuticals Other industry is in the same range as ATNM (100) in the Biotechnology industry. This means that OCUL’s stock grew similarly to ATNM’s over the last 12 months.

OCUL's SMR Rating (98) in the Pharmaceuticals Other industry is in the same range as ATNM (99) in the Biotechnology industry. This means that OCUL’s stock grew similarly to ATNM’s over the last 12 months.

ATNM's Price Growth Rating (64) in the Biotechnology industry is in the same range as OCUL (65) in the Pharmaceuticals Other industry. This means that ATNM’s stock grew similarly to OCUL’s over the last 12 months.

ATNM's P/E Growth Rating (100) in the Biotechnology industry is in the same range as OCUL (100) in the Pharmaceuticals Other industry. This means that ATNM’s stock grew similarly to OCUL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ATNMOCUL
RSI
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
77%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
75%
Bullish Trend 2 days ago
84%
Momentum
ODDS (%)
Bearish Trend 7 days ago
80%
Bearish Trend 2 days ago
80%
MACD
ODDS (%)
Bearish Trend 7 days ago
74%
Bearish Trend 2 days ago
82%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
85%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
88%
Advances
ODDS (%)
Bullish Trend 15 days ago
71%
Bullish Trend 22 days ago
78%
Declines
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 7 days ago
86%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
86%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
ATNM
Daily Signal:
Gain/Loss:
OCUL
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
TIREX18.140.27
+1.51%
Nuveen Real Estate Sec Sel R6
PRKQX7.490.07
+0.94%
PGIM Real Estate Income R6
JGEMX13.460.11
+0.82%
JHancock Global Equity R6
FWRLX12.38N/A
N/A
Fidelity Select Wireless
RRITX21.34-0.20
-0.93%
T. Rowe Price International Stock R

OCUL and

Correlation & Price change

A.I.dvisor indicates that over the last year, OCUL has been loosely correlated with LEGN. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if OCUL jumps, then LEGN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To OCUL
1D Price
Change %
OCUL100%
+0.47%
LEGN - OCUL
55%
Loosely correlated
-0.06%
CDXS - OCUL
55%
Loosely correlated
-2.94%
WVE - OCUL
54%
Loosely correlated
-2.70%
NRIX - OCUL
53%
Loosely correlated
-1.43%
NUVL - OCUL
53%
Loosely correlated
-2.03%
More